The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-19. Anything still debated is marked as such rather than presented as settled.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
== Related compounds == Cyclohexanehexone can be viewed as the neutral counterpart of the rhodizonate anion C6O2−6. The singly charged anion C6O−6 has been detected in mass spectrometry experiments, formed by oligomerization of carbon monoxide through the formation of molybdenum carbonyls. According to X-ray diffraction analysis, the reagent traded under the name "cyclohexanehexone octahydrate" or equivalent names is actually dodecahydroxycyclohexane dihydrate—the geminal diol derivative of the six ketone groups with an additional two molecules of water—a solid that decomposes at 95 °C. In 1966, Howard E. Worne of Natick Chemical Industries patented compounds with formulas C10O8 and C14O10, which can be described as the fusion of two or three molecules of C6O6, claimed to be produced by the action of ultraviolet radiation on a hot water solution of the parent compound.
Because ovulation is triggered by a surge in estradiol levels at mid-cycle, estrogen exposure during elagolix therapy might be greater around this time in some women. In addition to its activity as a GnRH antagonist, elagolix is a weak to moderate inducer of CYP3A and an inhibitor of P-glycoprotein. As a result, elagolix may affect the metabolism and/or transport of other medications, and this may contribute to drug interactions with elagolix.
Alkaptonuria Congenital disorders of joints Diabetes doubles the risk of having a joint replacement due to osteoarthritis, and people with diabetes have joint replacements at a younger age than those without diabetes. Ehlers–Danlos syndrome Injury to joints or ligaments (such as the ACL) Ligamentous deterioration or instability Marfan syndrome Obesity Joint infection
Hooters, Inc., was incorporated in Clearwater, Florida, on April 1, 1983, by six Clearwater businessmen: Lynn D. Stewart, Gil DiGiannantonio, Ed Droste, Billy Ranieri, Ken Wimmer and Dennis Johnson. The date was an April Fools' Day joke because the original six owners believed that their prospect was going to fail. Their first Hooters restaurant was built on the site of a former rundown nightclub that had been purchased at a low price. So many businesses had folded in that particular location that the Hooters founders built a small "graveyard" at the front door for each that had come and gone before them. The first restaurant opened its doors on October 4, 1983, in Clearwater. This original location was decorated with memorabilia from Waverly, Iowa, hometown to some of the original Hooters 6. In December 1984, Hugh Connerty bought the rights to Hooters from the Original Hooters 6. Robert H. Brooks and a group of Atlanta investors (operators of Hooters of America, Inc.) bought out Hugh Connerty. In 2002, Brooks bought majority control and became chairman. The Clearwater-based company retained control over restaurants in the Tampa Bay Area, Chicago metropolitan area, and one in Manhattan, as well as rights to develop a Hooters casino and sell sauces in grocery stores, while all other locations were under the aegis of Hooters of America, which sold franchising rights to the rest of the United States and international locations. Under Brooks's leadership, the collective Hooters brand expanded to more than 425 stores worldwide.
=== Blockade for diseases with a chronic immunological component === As increasingly documented, the SP-NK1R system induces or modulates many aspects of the immune response, including WBC production and activation, and cytokine expression, Reciprocally, cytokines may induce expression of SP and its NK1R. In this sense, for diseases in which a pro-inflammatory component has been identified or strongly suspected, and for which current treatments are absent or in need of improvement, abrogation of the SP-NK1 system continues to receive focus as a treatment strategy. Currently, the only completely developed method available in that regard is antagonism (blockade, inhibition) of the SP preferring receptor, i.e., by drugs known as neurokinin type 1 antagonists (also termed: SP antagonists, or tachykinin antagonists.) One such drug is aprepitant to prevent the nausea and vomiting that accompanies chemotherapy, typically for cancer. With the exception of chemotherapy-induced nausea and vomiting, the patho-physiological basis of many of the disease groups listed below, for which NK1RAs have been studied as a therapeutic intervention, are to varying extents hypothesized to be initiated or advanced by a chronic non-homeostatic inflammatory response.
Sources: en.wikipedia.org
Anabolic-androgenic steroids (AAS) were first isolated, identified and synthesized in the 1930s, and are now used therapeutically in medicine to induce bone growth, stimulate appetite, induce male puberty, and treat chronic wasting conditions, such as cancer and AIDS. Anabolic steroids also increase muscle mass and physical strength, and are therefore used in sports and bodybuilding to enhance strength or physique. Known side effects include harmful changes in cholesterol levels (increased low-density lipoprotein and decreased high-density lipoprotein), acne, high blood pressure, and liver damage. Some of these effects can be mitigated by taking supplemental drugs. AAS use in American sports began in October 1954 when John Ziegler, a doctor who treated American athletes, went to Vienna with the American weightlifting team. There he met a Russian physician who, over "a few drinks", repeatedly asked "What are you giving your boys?" When Ziegler returned the question, the Russian said that his own athletes were being given testosterone. Returning to America, Ziegler tried low doses of testosterone on himself, on the American trainer Bob Hoffman and on two lifters, Jim Park and Yaz Kuzahara. All gained more weight and strength than any training programme would produce but there were side-effects. Ziegler sought a drug without after-effects and hit upon the anabolic steroid methandrostenolone, first made in the US in 1958 by Ciba and marketed as Dianabol (colloquially known as "d-bol").
Structured instruments, as Global Appraisal of Individual Needs - Short Screener-GAIN-SS and Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV-PRISM, have been developed to increase the diagnostic validity. While structured instruments can help organize diagnostic information, clinicians must still make judgments on the origin of symptoms.
The 16-bit A register is the primary arithmetic and logic accumulator. The 16-bit B register is used for double-length arithmetic operations. The 16-bit program counter holds the address of the next instruction. A carry flag indicates arithmetic overflow. A 16-bit X index register provides for modification of the address of operands. The instruction set has 72 arithmetic, logic, I/O and flow-control instructions. Input/output instructions use the A register and separate input and output 16-bit buses. A 10-bit I/O control bus, consisting of 6 bits of device address information and 4 bits of function selection, is used. The basic processor has a single interrupt signal line, and an option provided up to 48 interrupts. In addition to a front-panel display of lights and toggle switches, the system supports different types of input/output devices. A Teletype Model 33 ASR teleprinter can be used as a console I/O device and (in the most basic systems) to load and store data to paper tape. Smaller systems typically use a high-speed paper-tape reader and punch for data storage. The Honeywell family of peripherals included card readers and punches, line printers, magnetic tape, and both fixed-head and removable hard disk drives. A rack-mounted configuration weighs around 120 pounds (54 kg) and used 475 watts of power. Honeywell advertised the system as the first minicomputer selling for less than $10,000. The Honeywell 316 has the distinction of being the first computer displayed at a computer show with semiconductor RAM memory.
=== Chemistry and biochemistry === Chemical synthesis, the execution of chemical reactions to form a more complex molecule from chemical precursors Organic synthesis, the chemical synthesis of organic compounds Total synthesis, the complete organic synthesis of complex organic compounds, usually without the aid of biological processes Convergent synthesis or linear synthesis, a strategy to improve the efficiency of multi-step chemical syntheses Dehydration synthesis, a chemical synthesis resulting in the loss of a water molecule Biosynthesis, the creation of an organic compound in a living organism, usually aided by enzymes Photosynthesis, a biochemical reaction using a carbon molecule to produce an organic molecule, using sunlight as a catalyst Chemosynthesis, the synthesis of biological compounds into organic waste, using methane or an oxidized molecule as a catalyst Amino acid synthesis, the synthesis of an amino acid from its constituents Peptide synthesis, the biochemical synthesis of peptides using amino acids Protein biosynthesis, the multi-step biochemical synthesis of proteins (long peptides) DNA synthesis, several biochemical processes for making DNA DNA replication, DNA biosynthesis in vivo Synthesis (cell cycle) RNA synthesis, the synthesis of RNA from nucleic acids, using another nucleic acid chain as a template ATP synthesis, the biochemical synthesis of ATP
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.